Back to results
US 2025/0205263 A1Published application
Oral composition comprising b-escin and the use thereof
AssigneeEscilab Sp Z O. O.
InventorKatarzyna KOZIAK
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeEscilab Sp Z O. O.
InventorKatarzyna KOZIAK
Estimating the term…
The present invention relates to a field of treatment and prevention of overweight and obesity. In particular the present invention is directed to an oral composition comprising (beta)-escin (beta-escin) for use in prevention of extracellular to intracellular water ratio (ECW/ICW) increase in weight loss interventions in treatment of overweight and obesity. Therefore, the composition of the invention has a beneficial effect on fluid distribution during weight loss. The composition of the invention not only improves ECW/ICW ratio but also includes an anorectic effect and results in appetite suppression. Therefore, it is useful alone as overweight and obesity intervention.
A method for prevention of extracellular to intracellular water ratio increase in weight loss interventions for treatment of overweight and obesity, comprising orally administering a composition comprising β-escin up to five times per day, during or after a meal, in a total dose from 0.015 to 0.20 mg β-escin/kg per day, and continuing said administration from at least 21 days to 6 months.
Dependencies are inferred from the claim text.